undamentalytics Newsletter

Summer Road LLC: insider trades

10% owner at Ocular Therapeutix, Inc. 16 open-market purchases and no sales not made under a pre-set plan, reported from March 17, 2020 to February 27, 2024.

Would copying Summer Road LLC’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 10 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on March 25, 2020 into $19,641 by November 2, 2026, +10.8% a year. The copy held shares only 51% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $20,075, +11.2% a year (the S&P 500 held throughout made $33,515, +20.1% a year). Beta against the index was 0.88. Twelve months after each report, the average purchase was +0.9% against the S&P 500 (median −22.5%), and 30% beat it. Measured from the trade date, the insider’s own timing, the average was −20.1%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 2020202120222023202420252026 $33.5k$20.1k$19.6k
Copying Summer Road LLCS&P 500, same days investedS&P 500, held throughout $10,000 copying Summer Road LLC’s open-market purchases from March 25, 2020, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+10.8%
S&P 500, same days invested
+11.2% (held throughout +20.1%)
Time in shares
51%
Sharpe ratio (S&P 500)
0.40 (0.96)
Biggest drop (S&P 500)
−77% (−25%)
Market sensitivity (beta)
0.88
Purchases copied
10

Trade by trade

Summer Road LLC: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 10 −15.9% −22.7% 20% 4 −1.09 0.36 No reliable evidence
Purchases, 6 months after the report 10 −3.7% −12.9% 30% 4 −0.10 0.93 No reliable evidence
Purchases, 12 months after the report 10 +0.9% −22.5% 30% 4 0.06 0.95 No reliable evidence
Purchases, 12 months after the trade 8 −20.1% −31.2% 13% 4 −0.33 0.77 No reliable evidence
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Ocular Therapeutix, Inc OCUL —160March 17, 2020February 27, 2024

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
February 27, 2024February 26, 2024 OCUL Purchase $7,000,000 −45.2%−57.2%−47.0%
December 18, 2023December 14, 2023 OCUL Purchase $4,999,998 not yetnot yetnot yet
November 9, 2022November 7, 2022 OCUL Purchase $25,648 not yetnot yetnot yet
October 12, 2022October 10, 2022 OCUL Purchase $79,000 not yetnot yetnot yet
September 29, 2022September 27, 2022 OCUL Purchase $689,272 not yetnot yetnot yet
February 23, 2022February 18, 2022 OCUL Purchase $248,000 −35.1%+18.5%not yet
January 31, 2022January 27, 2022 OCUL Purchase $28,600 −21.4%−19.5%−20.4%
January 24, 2022January 20, 2022 OCUL Purchase $405,633 −25.7%−25.6%−22.1%
January 18, 2022January 13, 2022 OCUL Purchase $302,996 −32.5%−19.2%−20.0%
December 16, 2021December 14, 2021 OCUL Purchase $282,331 −24.0%−46.5%−40.8%
December 14, 2021December 10, 2021 OCUL Purchase $267,815 −12.5%−42.5%−43.6%
December 8, 2021December 6, 2021 OCUL Purchase $376,603 −12.5%−47.3%−40.2%
May 21, 2020May 19, 2020 OCUL Purchase $1,999,998 +0.5%+50.0%+73.0%
March 24, 2020March 20, 2020 OCUL Purchase $514,493 +49.5%+198.7%not yet
March 20, 2020March 18, 2020 OCUL Purchase $1,782,981 not yetnot yetnot yet
March 17, 2020March 13, 2020 OCUL Purchase $4,347,134 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Summer Road LLC traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.